CRS-207
- Generic Name
- CRS-207
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- JJX4JHS4PO
- Associated Conditions
- -
- Associated Therapies
- -
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-04-09
- Target Recruit Count
- 17
- Registration Number
- NCT05014776
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 61
- Registration Number
- NCT03190265
- Locations
- 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-10-08
- Target Recruit Count
- 41
- Registration Number
- NCT03006302
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath